Botox Maker to Pay $600 Million in Settlement Over Off-Label Uses
Allergan has agreed to pay $600 million in criminal and civil penalties and plead guilty to one misdemeanor count of "misbranding" its drug Botox as part of a global settlement with the federal government over off-label uses of the drug. As part of the plea deal, Allergan agreed to drop its First Amendment legal action against the government, which critics said threatened the entire federal regulation of pharmaceuticals.
